市場調査レポート

商品コード

がん遺伝子治療の世界市場規模、シェア、業界動向分析：治療法別、エンドユーザー別、地域別の展望と予測（2022年～2028年）

Global Cancer Gene Therapy Market Size, Share & Industry Trends Analysis Report By Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer), By End User, By Regional Outlook and Forecast, 2022 - 2028

出版日: 2022年04月29日 | 発行: KBV Research

| ページ情報: 英文 153 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 3,600 559,512円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 4,320 671,414円

レポートPDFを同一企業内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprisewide License)

USD 6,048 939,980円

レポートPDFを同一企業のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.42円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のがん遺伝子治療の市場規模は、2028年までに50億米ドルに達し、予測期間中にCAGR21.2%で成長すると予測されています。

市場の成長の主な要因は、がんの罹患率が上昇とがん研究への投資の拡大です。一方で、がん遺伝子治療の高コストが市場成長の妨げとなっています。

当レポートでは、世界のがん遺伝子治療市場について調査し、市場に影響を与える主な要因、競合分析、セグメント・地域別の市場分析、主要企業のプロファイルなどの情報を提供しています。

LIST OF TABLES

TABLE 1 Global Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 2 Global Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 3 Global Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 4 Global Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 5 Global Gene Induced Immunotherapy Market by Region, 2018 - 2021, USD Million
TABLE 6 Global Gene Induced Immunotherapy Market by Region, 2022 - 2028, USD Million
TABLE 7 Global Oncolytic Virotherapy Market by Region, 2018 - 2021, USD Million
TABLE 8 Global Oncolytic Virotherapy Market by Region, 2022 - 2028, USD Million
TABLE 9 Global Gene Transfer Market by Region, 2018 - 2021, USD Million
TABLE 10 Global Gene Transfer Market by Region, 2022 - 2028, USD Million
TABLE 11 Global Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 12 Global Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 13 Global Hospitals Market by Region, 2018 - 2021, USD Million
TABLE 14 Global Hospitals Market by Region, 2022 - 2028, USD Million
TABLE 15 Global Diagnostic centers Market by Region, 2018 - 2021, USD Million
TABLE 16 Global Diagnostic centers Market by Region, 2022 - 2028, USD Million
TABLE 17 Global Research Institutes Market by Region, 2018 - 2021, USD Million
TABLE 18 Global Research Institutes Market by Region, 2022 - 2028, USD Million
TABLE 19 Global Cancer Gene Therapy Market by Region, 2018 - 2021, USD Million
TABLE 20 Global Cancer Gene Therapy Market by Region, 2022 - 2028, USD Million
TABLE 21 North America Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 22 North America Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 23 North America Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 24 North America Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 25 North America Gene Induced Immunotherapy Market by Country, 2018 - 2021, USD Million
TABLE 26 North America Gene Induced Immunotherapy Market by Country, 2022 - 2028, USD Million
TABLE 27 North America Oncolytic Virotherapy Market by Country, 2018 - 2021, USD Million
TABLE 28 North America Oncolytic Virotherapy Market by Country, 2022 - 2028, USD Million
TABLE 29 North America Gene Transfer Market by Country, 2018 - 2021, USD Million
TABLE 30 North America Gene Transfer Market by Country, 2022 - 2028, USD Million
TABLE 31 North America Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 32 North America Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 33 North America Hospitals Market by Country, 2018 - 2021, USD Million
TABLE 34 North America Hospitals Market by Country, 2022 - 2028, USD Million
TABLE 35 North America Diagnostic centers Market by Country, 2018 - 2021, USD Million
TABLE 36 North America Diagnostic centers Market by Country, 2022 - 2028, USD Million
TABLE 37 North America Research Institutes Market by Country, 2018 - 2021, USD Million
TABLE 38 North America Research Institutes Market by Country, 2022 - 2028, USD Million
TABLE 39 North America Cancer Gene Therapy Market by Country, 2018 - 2021, USD Million
TABLE 40 North America Cancer Gene Therapy Market by Country, 2022 - 2028, USD Million
TABLE 41 US Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 42 US Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 43 US Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 44 US Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 45 US Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 46 US Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 47 Canada Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 48 Canada Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 49 Canada Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 50 Canada Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 51 Canada Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 52 Canada Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 53 Mexico Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 54 Mexico Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 55 Mexico Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 56 Mexico Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 57 Mexico Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 58 Mexico Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 59 Rest of North America Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 60 Rest of North America Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 61 Rest of North America Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 62 Rest of North America Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 63 Rest of North America Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 64 Rest of North America Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 65 Europe Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 66 Europe Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 67 Europe Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 68 Europe Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 69 Europe Gene Induced Immunotherapy Market by Country, 2018 - 2021, USD Million
TABLE 70 Europe Gene Induced Immunotherapy Market by Country, 2022 - 2028, USD Million
TABLE 71 Europe Oncolytic Virotherapy Market by Country, 2018 - 2021, USD Million
TABLE 72 Europe Oncolytic Virotherapy Market by Country, 2022 - 2028, USD Million
TABLE 73 Europe Gene Transfer Market by Country, 2018 - 2021, USD Million
TABLE 74 Europe Gene Transfer Market by Country, 2022 - 2028, USD Million
TABLE 75 Europe Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 76 Europe Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 77 Europe Hospitals Market by Country, 2018 - 2021, USD Million
TABLE 78 Europe Hospitals Market by Country, 2022 - 2028, USD Million
TABLE 79 Europe Diagnostic centers Market by Country, 2018 - 2021, USD Million
TABLE 80 Europe Diagnostic centers Market by Country, 2022 - 2028, USD Million
TABLE 81 Europe Research Institutes Market by Country, 2018 - 2021, USD Million
TABLE 82 Europe Research Institutes Market by Country, 2022 - 2028, USD Million
TABLE 83 Europe Cancer Gene Therapy Market by Country, 2018 - 2021, USD Million
TABLE 84 Europe Cancer Gene Therapy Market by Country, 2022 - 2028, USD Million
TABLE 85 Germany Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 86 Germany Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 87 Germany Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 88 Germany Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 89 Germany Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 90 Germany Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 91 UK Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 92 UK Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 93 UK Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 94 UK Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 95 UK Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 96 UK Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 97 France Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 98 France Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 99 France Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 100 France Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 101 France Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 102 France Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 103 Russia Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 104 Russia Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 105 Russia Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 106 Russia Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 107 Russia Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 108 Russia Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 109 Spain Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 110 Spain Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 111 Spain Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 112 Spain Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 113 Spain Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 114 Spain Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 115 Italy Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 116 Italy Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 117 Italy Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 118 Italy Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 119 Italy Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 120 Italy Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 121 Rest of Europe Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 122 Rest of Europe Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 123 Rest of Europe Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 124 Rest of Europe Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 125 Rest of Europe Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 126 Rest of Europe Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 127 Asia Pacific Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 128 Asia Pacific Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 129 Asia Pacific Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 130 Asia Pacific Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 131 Asia Pacific Gene Induced Immunotherapy Market by Country, 2018 - 2021, USD Million
TABLE 132 Asia Pacific Gene Induced Immunotherapy Market by Country, 2022 - 2028, USD Million
TABLE 133 Asia Pacific Oncolytic Virotherapy Market by Country, 2018 - 2021, USD Million
TABLE 134 Asia Pacific Oncolytic Virotherapy Market by Country, 2022 - 2028, USD Million
TABLE 135 Asia Pacific Gene Transfer Market by Country, 2018 - 2021, USD Million
TABLE 136 Asia Pacific Gene Transfer Market by Country, 2022 - 2028, USD Million
TABLE 137 Asia Pacific Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 138 Asia Pacific Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 139 Asia Pacific Hospitals Market by Country, 2018 - 2021, USD Million
TABLE 140 Asia Pacific Hospitals Market by Country, 2022 - 2028, USD Million
TABLE 141 Asia Pacific Diagnostic centers Market by Country, 2018 - 2021, USD Million
TABLE 142 Asia Pacific Diagnostic centers Market by Country, 2022 - 2028, USD Million
TABLE 143 Asia Pacific Research Institutes Market by Country, 2018 - 2021, USD Million
TABLE 144 Asia Pacific Research Institutes Market by Country, 2022 - 2028, USD Million
TABLE 145 Asia Pacific Cancer Gene Therapy Market by Country, 2018 - 2021, USD Million
TABLE 146 Asia Pacific Cancer Gene Therapy Market by Country, 2022 - 2028, USD Million
TABLE 147 China Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 148 China Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 149 China Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 150 China Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 151 China Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 152 China Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 153 Japan Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 154 Japan Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 155 Japan Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 156 Japan Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 157 Japan Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 158 Japan Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 159 India Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 160 India Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 161 India Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 162 India Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 163 India Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 164 India Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 165 South Korea Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 166 South Korea Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 167 South Korea Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 168 South Korea Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 169 South Korea Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 170 South Korea Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 171 Singapore Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 172 Singapore Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 173 Singapore Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 174 Singapore Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 175 Singapore Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 176 Singapore Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 177 Malaysia Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 178 Malaysia Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 179 Malaysia Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 180 Malaysia Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 181 Malaysia Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 182 Malaysia Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 183 Rest of Asia Pacific Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 184 Rest of Asia Pacific Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 185 Rest of Asia Pacific Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 186 Rest of Asia Pacific Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 187 Rest of Asia Pacific Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 188 Rest of Asia Pacific Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 189 LAMEA Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 190 LAMEA Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 191 LAMEA Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 192 LAMEA Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 193 LAMEA Gene Induced Immunotherapy Market by Country, 2018 - 2021, USD Million
TABLE 194 LAMEA Gene Induced Immunotherapy Market by Country, 2022 - 2028, USD Million
TABLE 195 LAMEA Oncolytic Virotherapy Market by Country, 2018 - 2021, USD Million
TABLE 196 LAMEA Oncolytic Virotherapy Market by Country, 2022 - 2028, USD Million
TABLE 197 LAMEA Gene Transfer Market by Country, 2018 - 2021, USD Million
TABLE 198 LAMEA Gene Transfer Market by Country, 2022 - 2028, USD Million
TABLE 199 LAMEA Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 200 LAMEA Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 201 LAMEA Hospitals Market by Country, 2018 - 2021, USD Million
TABLE 202 LAMEA Hospitals Market by Country, 2022 - 2028, USD Million
TABLE 203 LAMEA Diagnostic centers Market by Country, 2018 - 2021, USD Million
TABLE 204 LAMEA Diagnostic centers Market by Country, 2022 - 2028, USD Million
TABLE 205 LAMEA Research Institutes Market by Country, 2018 - 2021, USD Million
TABLE 206 LAMEA Research Institutes Market by Country, 2022 - 2028, USD Million
TABLE 207 LAMEA Cancer Gene Therapy Market by Country, 2018 - 2021, USD Million
TABLE 208 LAMEA Cancer Gene Therapy Market by Country, 2022 - 2028, USD Million
TABLE 209 Brazil Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 210 Brazil Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 211 Brazil Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 212 Brazil Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 213 Brazil Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 214 Brazil Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 215 Argentina Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 216 Argentina Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 217 Argentina Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 218 Argentina Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 219 Argentina Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 220 Argentina Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 221 UAE Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 222 UAE Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 223 UAE Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 224 UAE Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 225 UAE Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 226 UAE Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 227 Saudi Arabia Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 228 Saudi Arabia Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 229 Saudi Arabia Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 230 Saudi Arabia Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 231 Saudi Arabia Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 232 Saudi Arabia Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 233 South Africa Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 234 South Africa Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 235 South Africa Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 236 South Africa Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 237 South Africa Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 238 South Africa Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 239 Nigeria Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 240 Nigeria Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 241 Nigeria Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 242 Nigeria Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 243 Nigeria Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 244 Nigeria Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 245 Rest of LAMEA Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 246 Rest of LAMEA Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 247 Rest of LAMEA Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 248 Rest of LAMEA Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 249 Rest of LAMEA Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 250 Rest of LAMEA Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 251 Key Information - Novartis AG
TABLE 252 Key Information - GlaxoSmithKline PLC (GSK)
TABLE 253 Key Information - Amgen, Inc.
TABLE 254 Key Information - Bristol Myers Squibb Company
TABLE 255 key Information - Karyopharm Therapeutics, Inc.
TABLE 256 Key Information - Gilead Sciences, Inc.
TABLE 257 Key information - Adaptimmune Limited
TABLE 258 Key Information - Genelux Corporation
TABLE 259 key information - Sarepta Therapeutics, Inc.

List of Figures

FIG 1 Methodology for the research
FIG 2 Global Cancer Gene Therapy Market Size, By Therapy, 2018 - 2028, USD Million
FIG 3 Global Cancer Gene Therapy Market Share, By Therapy, 2021
FIG 4 Global Cancer Gene Therapy Market Share, By Therapy, 2028
FIG 5 Global Cancer Gene Therapy Market Size, By End User, 2018 - 2028, USD Million
FIG 6 Global Cancer Gene Therapy Market Share, By End User, 2021
FIG 7 Global Cancer Gene Therapy Market Share, By End User, 2028
FIG 8 Global Cancer Gene Therapy Market Size, By Region, 2018 - 2028, USD Million
FIG 9 Global Cancer Gene Therapy Market Share, By Region, 2021
FIG 10 Global Cancer Gene Therapy Market Share, By Region, 2028
FIG 11 Recent strategies and developments: Novartis AG
FIG 12 Recent strategies and developments: Bristol Myers Squibb Company

The Global Cancer Gene Therapy Market size is expected to reach $5 billion by 2028, rising at a market growth of 21.2% CAGR during the forecast period.

Gene therapy is the process of replacing faulty or damaged genes at the molecular level. It is a procedure in which viruses are genetically modified before being transmitted to host cells. Viruses are genetically modified to contain a gene that is now frequently used to cure cancer. The pipeline for cancer gene therapy is quite strong, and various industry participants have recently concentrated their efforts on developing a number of successful cancer gene therapies and vectors. Pre-marketing approval is required for the marketing of cancer gene therapy, and it is a lengthy process that is closely reviewed. As a result, there are few cancer gene treatments on the market, and they are still in development. However, vectors, which are essential for gene transfer and are pre-requisites for gene therapy, are increasingly being used in study and treatment.

Cancer is described as uncontrolled cell development in the body that results in organ failure. It can be fatal if left untreated. The body manages uncontrolled cell proliferation in numerous ways, one of which is by deploying white blood cells to detect and kill malignant cells. The immune system has been discovered to be influenced in order to cause malignant cells to self-destruct. The effects of radiation and chemotherapy therapy on malignant cells in the body are constant and dependable. Immunotherapy for hematological tumors has recently gained popularity and is attracting the attention of numerous researchers. Scientists have devised a method for isolating, replicating, and developing cancer-destroying cells from a patient's blood cancer and then injecting those cells back into the patient to eliminate their tumors, resulting in long-term remissions.

Cancer has a strong tendency to spread throughout the body. It is the world's second-leading cause of death. Cancer gene therapy is a strategy for treating cancer that involves inserting therapeutic DNA into the patient's gene. Cancer gene therapy has grown in popularity as a result of its high success rate in preclinical and clinical trials. A treatment in which the mutant gene is replaced with a healthy gene or the deactivation of a gene whose function is improper are examples of cancer gene therapy procedures. A new strategy for combating cancer cells has just been devised, in which new genes are delivered into the body.

COVID-19 Impact

The COVID-19 pandemic has hampered the market for cancer gene therapy. Doctors from Dana Farber Cancer Institute discovered that during the COVID-19 pandemic, there was a 46 percent decline in diagnoses of the six most frequent cancer types - breast, pancreatic, colorectal, lung, gastric, and oesophageal cancers, according to research published in Cancer Connect 2020. Furthermore, the Centres for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health-prevention services, as well as elective surgeries, be postponed unless the risks outweighed the benefits, in order to secure hospital infrastructure for COVID-19 patients' treatment. As a result, the COVID-19 pandemic has had an influence on the market for cancer gene therapy.

Market Growth Factors

Growing cases of Cancer

In recent years, there has been a rising burden of cancer disease, the expanding focus on research to create an effective cancer treatment, and growing investments in cancer research. According to Globocan 2020, an expected 19,292,789 new cancer cases and 9,958,133 cancer-related deaths were reported worldwide in 2020. Various gene therapy strategies are now being used in the treatment of cancer. Anti-angiogenic gene therapy, pro-drug activating suicide gene therapy, gene therapy-based immune modulation, oncolytic virotherapy, gene correction/compensation, antisense, genetic manipulation of apoptotic and tumor invasion pathways, and RNAi techniques are only a few examples. These medicines have been used to treat cancers such as brain, lung, breast, pancreas, liver, prostate, colorectal, bladder, head & neck, skin, ovarian, and renal cancer.

Supportive regulations

An improving regulatory landscape would help the industry players to optimize the opportunities. In addition, manufacturers are subject to regulations to secure the admission of defect-free products (vectors) onto the market, as they are associated with people's health. Because any flaws in gene therapy goods could be lethal to patients, laws have been changed to ensure that no products are recalled during post-market surveillance. Better success rates of novel medicines, ethical acceptance of gene therapy for cancer treatment, and enormous unexplored markets in emerging nations are expected to impact the market in the long run.

Market Restraining Factors

High cost of Cancer Gene Therapy

Gene therapy can be very expensive, thereby discouraging many people from choosing this mode of treatment. In the United States, for example, Zolgensma, gene therapy for spinal muscular atrophy, is the most expensive drug. In many countries, people have low disposable income, so spending high costs on healthcare is still a distant dream for them. Moreover, many governments are reeling from the negative impacts brought by the COVID-19 pandemic on their economy and healthcare infrastructure. The high expense of cancer gene therapy is due to the need for extensive clinical studies; also, unlike other pharmaceuticals, treatment by cancer gene therapy varies from person to person depending on the genetic acceptance of each patient.

Therapy Outlook

Based on Therapy, the market is segmented into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. In 2021, the Gene Transfer segment held a promising revenue share of the Cancer Gene Therapy Market. Gene transfer is a new treatment method that involves introducing new modified genes into malignant cells or associated tissue in order to kill the cells or restrict their growth. This method is adaptable, as it may be employed with a wide range of vectors and genes in clinical trials with positive results. Gene therapy could be utilized alone or in combination with other treatments to control the condition as technology advances. Naked/plasmid vectors, electroporation, sonoporation, magnetoreception, and gene gun are all used to transfer or replace genes.

End User Outlook

Based on End User, the market is segmented into Hospitals, Diagnostic centers and Research Institutes. In 2021, the hospital segment collected the maximum revenue share of the Cancer Gene Therapy Market. This is owing to rising healthcare awareness, an increase in the number of hospitals, and an increase in the geriatric and bariatric populations. Therefore, these factors would continue to boost the growth of the segment even during the forecasting period.

Regions Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2021, the North America emerged as the leading region in the overall Cancer Gene Therapy Market by procuring the highest revenue share of the market. The growth of the regional market is owing to the huge investments in research and technological breakthroughs. The region's viral vectors and plasmid DNA market is boosted by the presence of a huge population base, government measures to develop healthcare facilities, and a rise in healthcare expenditure.

Strategies Deployed in Cancer Gene Therapy Market

Apr-2022: Kite, a Gilead Company received approval from U.S. Food and Drug Administration (FDA) for Yescarta CAR T-cell therapy. This approval focused on adult patients with huge B-cell lymphoma that is disobedient to first-line chemoimmunotherapy or that worsen within 12 months of starting chemoimmunotherapy.

Mar-2022: Novartis signed an agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics. This agreement aimed to launch HER 2 targeted CAR-M cell therapy, which is certified in basic tests for the therapy of solid tumors. Additionally, The Global Biotech Cooperations unit of Novartis is completed engaged to collaborate with Carisma Therapeutics to carry CAR-M cell treatments to patients by providing its proven state-of-the-art cell and gene manufacturing abilities.

Dec-2021: Novartis signed an agreement to acquire Gyroscope Therapeutics, a clinical-stage gene therapy company. Through this acquisition, Novartis would achieve access to the prior guide experimental gene treatment, GT005.

Dec-2021: Novartis unveiled T-Charge, the organization's next-generation CAR-T platform. The platform would offer a base for diverse new investigational CAR-T cell treatments in the Novartis pipeline. Additionally, the T-Charge platform conserves T cell stemness, the capabilities to mature and renew, which results in a product embracing greater proliferative potential and lesser exhausted T cells. Moreover, T-Charge, CAR-T cell growth occurs mainly within a patient's body, reducing the need for an extended culture time outside of the body. Furthermore, the unique attribute of the T-Charge platform may guide to superior and more strong responses, enhance long-term conclusion and a minimize danger of harsh adverse events.

Mar-2021: Novartis received an approval from Health Sciences Authority for Kymriah as the first economic chimeric antigen receptor T-cell therapy. Additionally, Kymriah, a CD19-directed constitutionally customized autologous T-cell immunocellular therapy, is accepted to treat two fatal cancers that have restricted treatment choices and historically worst conclusions, addressing the crucial demand for new treatments for patients.

Mar-2021: Bristol Myers Squibb along with bluebird bio received a U.S. Food and Drug Administration has approved Abecma, as the first B-cell maturation antigen directed chimeric antigen receptor T cell immunotherapy. The approval offers medication for adult patients with refractory or relapsed various myeloma after four or more preceding lines of therapy, such as a proteasome inhibitor, an anti-CD38 monoclonal antibody, and an immunomodulatory agent. Additionally, Abecma is a customized immune cell therapy accepted as a one-time mixture with an approved dose range of 300 to 460 x 106 CAR-positive T cells.

Jan-2020: Adapta Immue signed a co-development and co-commercialization agreement with Astellas Pharma, a Japanese multinational pharmaceutical company. Through this agreement, the companies aimed to launch new stem-cell concluded allogeneic T-cell therapies for patients with cancer. Additionally, the collaboration would use Adaptimmune's target recognition and affirmation abilities for creating target-specific chimeric antigen receptors, HLA-independent TCRs, and T-cell Receptors that identify surface epitopes freely of the HLA overview of the tumor cell.

Oct-2019: GlaxoSmithKline joined hands with Lyell Immunopharma, operator of a biotechnology company. Through this collaboration, the companies aimed to enhance cell therapies for cancer patients. Additionally, the collaboration would approach Lyell's technologies to further reinforce GSK's cell treatment pipeline, such as GSK3377794, which marks the NY-ESO-1 antigen that is announced around various cancer types.

Mar-2019: Bristol-Myers Squibb merged with Celgene, a pharmaceutical company that makes cancer and immunology drugs. Through this merger, Bristol-Myers Squibb would acquire Celgene to build a dominant concentrated specialty biopharma enterprise well positioned to meet the demands of patients with cancer, immunologic, inflammatory disease, and cardiovascular disease through great value creative medicines and dominating scientific abilities. Additionally, the integrated enterprise would provide global scale and reach, preserving the agility and speed that is core to each enterprise's strategic access.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, GlaxoSmithKline PLC (GSK), Amgen, Inc., Bristol Myers, Squibb Company, Karyopharm Therapeutics, Inc., Gilead Sciences, Inc., Adaptimmune Limited, Genelux Corporation, and Sarepta Therapeutics, Inc

Scope of the Study

Market Segments covered in the Report:

By Therapy

Gene Induced Immunotherapy
Oncolytic Virotherapy, and
Gene Transfer

By End User

Hospitals
Diagnostic centers
Research Institutes

By Geography

North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA

Companies Profiled

Novartis AG
GlaxoSmithKline PLC (GSK)
Amgen, Inc.
Bristol Myers Squibb Company
Karyopharm Therapeutics, Inc.
Gilead Sciences, Inc.
Adaptimmune Limited
Genelux Corporation
Sarepta Therapeutics, Inc.

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Global Cancer Gene Therapy Market, by Therapy
- 1.4.2 Global Cancer Gene Therapy Market, by End User
- 1.4.3 Global Cancer Gene Therapy Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview

2.1 Introduction
- 2.1.1 Overview
  - 2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints

Chapter 3. Global Cancer Gene Therapy Market by Therapy

3.1 Global Gene Induced Immunotherapy Market by Region
3.2 Global Oncolytic Virotherapy Market by Region
3.3 Global Gene Transfer Market by Region

Chapter 4. Global Cancer Gene Therapy Market by End User

4.1 Global Hospitals Market by Region
4.2 Global Diagnostic centers Market by Region
4.3 Global Research Institutes Market by Region

Chapter 5. Global Cancer Gene Therapy Market by Region

5.1 North America Cancer Gene Therapy Market
- 5.1.1 North America Cancer Gene Therapy Market by Therapy
  - 5.1.1.1 North America Gene Induced Immunotherapy Market by Country
  - 5.1.1.2 North America Oncolytic Virotherapy Market by Country
  - 5.1.1.3 North America Gene Transfer Market by Country
- 5.1.2 North America Cancer Gene Therapy Market by End User
  - 5.1.2.1 North America Hospitals Market by Country
  - 5.1.2.2 North America Diagnostic centers Market by Country
  - 5.1.2.3 North America Research Institutes Market by Country
- 5.1.3 North America Cancer Gene Therapy Market by Country
  - 5.1.3.1 US Cancer Gene Therapy Market
    - 5.1.3.1.1 US Cancer Gene Therapy Market by Therapy
    - 5.1.3.1.2 US Cancer Gene Therapy Market by End User
  - 5.1.3.2 Canada Cancer Gene Therapy Market
    - 5.1.3.2.1 Canada Cancer Gene Therapy Market by Therapy
    - 5.1.3.2.2 Canada Cancer Gene Therapy Market by End User
  - 5.1.3.3 Mexico Cancer Gene Therapy Market
    - 5.1.3.3.1 Mexico Cancer Gene Therapy Market by Therapy
    - 5.1.3.3.2 Mexico Cancer Gene Therapy Market by End User
  - 5.1.3.4 Rest of North America Cancer Gene Therapy Market
    - 5.1.3.4.1 Rest of North America Cancer Gene Therapy Market by Therapy
    - 5.1.3.4.2 Rest of North America Cancer Gene Therapy Market by End User
5.2 Europe Cancer Gene Therapy Market
- 5.2.1 Europe Cancer Gene Therapy Market by Therapy
  - 5.2.1.1 Europe Gene Induced Immunotherapy Market by Country
  - 5.2.1.2 Europe Oncolytic Virotherapy Market by Country
  - 5.2.1.3 Europe Gene Transfer Market by Country
- 5.2.2 Europe Cancer Gene Therapy Market by End User
  - 5.2.2.1 Europe Hospitals Market by Country
  - 5.2.2.2 Europe Diagnostic centers Market by Country
  - 5.2.2.3 Europe Research Institutes Market by Country
- 5.2.3 Europe Cancer Gene Therapy Market by Country
  - 5.2.3.1 Germany Cancer Gene Therapy Market
    - 5.2.3.1.1 Germany Cancer Gene Therapy Market by Therapy
    - 5.2.3.1.2 Germany Cancer Gene Therapy Market by End User
  - 5.2.3.2 UK Cancer Gene Therapy Market
    - 5.2.3.2.1 UK Cancer Gene Therapy Market by Therapy
    - 5.2.3.2.2 UK Cancer Gene Therapy Market by End User
  - 5.2.3.3 France Cancer Gene Therapy Market
    - 5.2.3.3.1 France Cancer Gene Therapy Market by Therapy
    - 5.2.3.3.2 France Cancer Gene Therapy Market by End User
  - 5.2.3.4 Russia Cancer Gene Therapy Market
    - 5.2.3.4.1 Russia Cancer Gene Therapy Market by Therapy
    - 5.2.3.4.2 Russia Cancer Gene Therapy Market by End User
  - 5.2.3.5 Spain Cancer Gene Therapy Market
    - 5.2.3.5.1 Spain Cancer Gene Therapy Market by Therapy
    - 5.2.3.5.2 Spain Cancer Gene Therapy Market by End User
  - 5.2.3.6 Italy Cancer Gene Therapy Market
    - 5.2.3.6.1 Italy Cancer Gene Therapy Market by Therapy
    - 5.2.3.6.2 Italy Cancer Gene Therapy Market by End User
  - 5.2.3.7 Rest of Europe Cancer Gene Therapy Market
    - 5.2.3.7.1 Rest of Europe Cancer Gene Therapy Market by Therapy
    - 5.2.3.7.2 Rest of Europe Cancer Gene Therapy Market by End User
5.3 Asia Pacific Cancer Gene Therapy Market
- 5.3.1 Asia Pacific Cancer Gene Therapy Market by Therapy
  - 5.3.1.1 Asia Pacific Gene Induced Immunotherapy Market by Country
  - 5.3.1.2 Asia Pacific Oncolytic Virotherapy Market by Country
  - 5.3.1.3 Asia Pacific Gene Transfer Market by Country
- 5.3.2 Asia Pacific Cancer Gene Therapy Market by End User
  - 5.3.2.1 Asia Pacific Hospitals Market by Country
  - 5.3.2.2 Asia Pacific Diagnostic centers Market by Country
  - 5.3.2.3 Asia Pacific Research Institutes Market by Country
- 5.3.3 Asia Pacific Cancer Gene Therapy Market by Country
  - 5.3.3.1 China Cancer Gene Therapy Market
    - 5.3.3.1.1 China Cancer Gene Therapy Market by Therapy
    - 5.3.3.1.2 China Cancer Gene Therapy Market by End User
  - 5.3.3.2 Japan Cancer Gene Therapy Market
    - 5.3.3.2.1 Japan Cancer Gene Therapy Market by Therapy
    - 5.3.3.2.2 Japan Cancer Gene Therapy Market by End User
  - 5.3.3.3 India Cancer Gene Therapy Market
    - 5.3.3.3.1 India Cancer Gene Therapy Market by Therapy
    - 5.3.3.3.2 India Cancer Gene Therapy Market by End User
  - 5.3.3.4 South Korea Cancer Gene Therapy Market
    - 5.3.3.4.1 South Korea Cancer Gene Therapy Market by Therapy
    - 5.3.3.4.2 South Korea Cancer Gene Therapy Market by End User
  - 5.3.3.5 Singapore Cancer Gene Therapy Market
    - 5.3.3.5.1 Singapore Cancer Gene Therapy Market by Therapy
    - 5.3.3.5.2 Singapore Cancer Gene Therapy Market by End User
  - 5.3.3.6 Malaysia Cancer Gene Therapy Market
    - 5.3.3.6.1 Malaysia Cancer Gene Therapy Market by Therapy
    - 5.3.3.6.2 Malaysia Cancer Gene Therapy Market by End User
  - 5.3.3.7 Rest of Asia Pacific Cancer Gene Therapy Market
    - 5.3.3.7.1 Rest of Asia Pacific Cancer Gene Therapy Market by Therapy
    - 5.3.3.7.2 Rest of Asia Pacific Cancer Gene Therapy Market by End User
5.4 LAMEA Cancer Gene Therapy Market
- 5.4.1 LAMEA Cancer Gene Therapy Market by Therapy
  - 5.4.1.1 LAMEA Gene Induced Immunotherapy Market by Country
  - 5.4.1.2 LAMEA Oncolytic Virotherapy Market by Country
  - 5.4.1.3 LAMEA Gene Transfer Market by Country
- 5.4.2 LAMEA Cancer Gene Therapy Market by End User
  - 5.4.2.1 LAMEA Hospitals Market by Country
  - 5.4.2.2 LAMEA Diagnostic centers Market by Country
  - 5.4.2.3 LAMEA Research Institutes Market by Country
- 5.4.3 LAMEA Cancer Gene Therapy Market by Country
  - 5.4.3.1 Brazil Cancer Gene Therapy Market
    - 5.4.3.1.1 Brazil Cancer Gene Therapy Market by Therapy
    - 5.4.3.1.2 Brazil Cancer Gene Therapy Market by End User
  - 5.4.3.2 Argentina Cancer Gene Therapy Market
    - 5.4.3.2.1 Argentina Cancer Gene Therapy Market by Therapy
    - 5.4.3.2.2 Argentina Cancer Gene Therapy Market by End User
  - 5.4.3.3 UAE Cancer Gene Therapy Market
    - 5.4.3.3.1 UAE Cancer Gene Therapy Market by Therapy
    - 5.4.3.3.2 UAE Cancer Gene Therapy Market by End User
  - 5.4.3.4 Saudi Arabia Cancer Gene Therapy Market
    - 5.4.3.4.1 Saudi Arabia Cancer Gene Therapy Market by Therapy
    - 5.4.3.4.2 Saudi Arabia Cancer Gene Therapy Market by End User
  - 5.4.3.5 South Africa Cancer Gene Therapy Market
    - 5.4.3.5.1 South Africa Cancer Gene Therapy Market by Therapy
    - 5.4.3.5.2 South Africa Cancer Gene Therapy Market by End User
  - 5.4.3.6 Nigeria Cancer Gene Therapy Market
    - 5.4.3.6.1 Nigeria Cancer Gene Therapy Market by Therapy
    - 5.4.3.6.2 Nigeria Cancer Gene Therapy Market by End User
  - 5.4.3.7 Rest of LAMEA Cancer Gene Therapy Market
    - 5.4.3.7.1 Rest of LAMEA Cancer Gene Therapy Market by Therapy
    - 5.4.3.7.2 Rest of LAMEA Cancer Gene Therapy Market by End User

Chapter 6. Company Profiles

6.1 Novartis AG
- 6.1.1 Company Overview
- 6.1.2 Financial Analysis
- 6.1.3 Segmental and Regional Analysis
- 6.1.4 Research & Development Expense
6.2 GlaxoSmithKline PLC (GSK)
- 6.2.1 Company Overview
- 6.2.2 Financial Analysis
- 6.2.3 Segmental and Regional Analysis
- 6.2.4 Research & Development Expense
6.3 Amgen, Inc.
- 6.3.1 Company Overview
- 6.3.2 Financial Analysis
- 6.3.3 Regional Analysis
- 6.3.4 Research & Development Expenses
6.4 Bristol Myers Squibb Company
- 6.4.1 Company Overview
- 6.4.2 Financial Analysis
- 6.4.3 Regional Analysis
- 6.4.4 Research & Development Expenses
6.5 Karyopharm Therapeutics, Inc.
- 6.5.1 Company Overview
- 6.5.2 Financial Analysis
- 6.5.3 Research & Development Expense
6.6 Gilead Sciences, Inc.
- 6.6.1 Company overview
- 6.6.2 Financial Analysis
- 6.6.3 Research & Development Expenses
6.7 Adaptimmune Limited
- 6.7.1 Company Overview
- 6.7.2 Financial Analysis
- 6.7.3 Research & Development Expenses
6.8 Genelux Corporation
- 6.8.1 Company Overview
6.9 Sarepta Therapeutics, Inc.
- 6.9.1 Company Overview
- 6.9.2 Financial Analysis
- 6.9.3 Research & Development Expenses

がん遺伝子治療の世界市場規模、シェア、業界動向分析：治療法別、エンドユーザー別、地域別の展望と予測（2022年～2028年）

Global Cancer Gene Therapy Market Size, Share & Industry Trends Analysis Report By Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer), By End User, By Regional Outlook and Forecast, 2022 - 2028

目次

第1章市場の範囲と調査手法

第2章市場概要

第3章世界のがん遺伝子治療市場：治療別

第4章世界のがん遺伝子治療市場：エンドユーザー別

第5章世界のがん遺伝子治療市場：地域別

第6章企業プロファイル

LIST OF TABLES

Scope of the Study

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

Chapter 3. Global Cancer Gene Therapy Market by Therapy

Chapter 4. Global Cancer Gene Therapy Market by End User

Chapter 5. Global Cancer Gene Therapy Market by Region

Chapter 6. Company Profiles

がん遺伝子治療の世界市場規模、シェア、業界動向分析：治療法別、エンドユーザー別、地域別の展望と予測（2022年～2028年）

Global Cancer Gene Therapy Market Size, Share & Industry Trends Analysis Report By Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer), By End User, By Regional Outlook and Forecast, 2022 - 2028

目次

第1章 市場の範囲と調査手法

第2章 市場概要

第3章 世界のがん遺伝子治療市場：治療別

第4章 世界のがん遺伝子治療市場：エンドユーザー別

第5章 世界のがん遺伝子治療市場：地域別

第6章 企業プロファイル

LIST OF TABLES

Scope of the Study

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

Chapter 3. Global Cancer Gene Therapy Market by Therapy

Chapter 4. Global Cancer Gene Therapy Market by End User

Chapter 5. Global Cancer Gene Therapy Market by Region

Chapter 6. Company Profiles

第1章市場の範囲と調査手法

第2章市場概要

第3章世界のがん遺伝子治療市場：治療別

第4章世界のがん遺伝子治療市場：エンドユーザー別

第5章世界のがん遺伝子治療市場：地域別

第6章企業プロファイル